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Supplementary Figure S2. Miniaturisation of the radioactive ECM accumulation assay
The method to determine incorporation of radiolabelled amino acids into accumulated mature ECM was miniaturised successively using the culture areas and cell densities shown in A. The first phase of this assay optimisation used the traditional methodology: following culture of cells in media containing 14 C-labelled amino acids, excess radioactivity was removed by washing and cells lysed as described in materials and methods; the cell lysate was retained for protein measurement by BCA assay. Following extensive washing with PBS to remove cell debris, ECM was harvested using SDS or enzymatic methods and the radioactive decay of the solubilised ECM measured by liquid scintillation counting as per the scheme shown in B. In a further development, which removed the need for matrix harvest altogether, the assay was transferred to CytoStar-T scintillating microplates which use the principles of scintillation proximity assay technology, hence allowing the deposited matrix to be measured in situ, shown in C. This high-throughput approach was successfully applied in 96-and 384-well plate formats. Figure S3 . In situ staining of decellularised ECM using SYPRO Ruby is subject to photobleaching Photobleaching of decellularised ECM stained in situ was observed with SYPRO Ruby but not Flamingo. RPTEC in a 96 well plate were stimulated for 7 days with 10ng/mL TGFβ1. Matrix was decellularised as described in Materials and Methods and following fixation with 50% methanol/7% acetic acid for 2 hours, ECM stained in situ overnight using Flamingo (A) or SYPRO Ruby (B) was visualised using fluorescence microscopy. The entire well was excited and all 25 fields captured in a counter-clockwise spiral, starting from the centre of the well (field 1), as illustrated by the schematic (C).
There was marked bleaching of the outer fields in the wells stained with SYPRO Ruby but this did not occur in wells stained with Flamingo. The images in A and B show the entire well as a composite of the individual fields acquired from that well. Figure S4 . In situ fluorescent staining of decellularised ECM using Flamingo co-localises with matrix detected by collagen type I/III and fibronectin immunofluorescent staining (A) RPTEC were cultured in the presence of 10ng/mL TGFβ1 for 7 days. Fixed decellularised matrix was stained in situ with anti-fibronectin (EBioscience, clone FN-3) and anti-collagen I and III (Merck Millipore, AB745 and AB747). Anti-fibronectin was directly conjugated (Alexa Fluor488); anti-collagen type I and III were detected using Alexa Fluor647-conjugated anti-rabbit secondary antibody (Life Technologies). Images were acquired using a Cellomics Arrayscan HC reader using excitation/emission filter sets of 485nm/525nm and 650nm/684nm for fibronectin or collagen I/III, respectively. The panel on the right shows a merge of fibronectin (green) with collagen type I/III (blue). Figure S5 . Recombinant human Gremlin-1 dose-dependently inhibits the BMP4/7 response in HEK-Id1 reporter assay HEK293 cells stably transfected with an Id1-Luciferase reporter in the pGL4.26 vector (Promega) were maintained in DMEM + 10% FCS + 2mM L-Glutamine. For the luciferase assay, 5 x 10 4 cells/well were seeded into white poly-Dlysine coated 96 well plates (BD Biosciences) and incubated for 4 hours at 37°C to adhere. BMP4/7 heterodimer (R&D Systems) was reconstituted in 4mM HCl before being diluted into medium and was used at a final concentration of 100ng/mL. Gremlin-1 (R&D Systems) was added at the concentrations indicated. Plates were incubated for 24hr at 37°C before the luciferase signal was detected using SteadyGlo (Promega). Data have been normalised to show percentage inhibition of the maximal signal determined in the absence of Gremlin-1 and are plotted as mean ± SD for duplicate determinations. 
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